Aging Stereotypes and Prodromal Alzheimer's Disease

Mild Cognitive Impairment (MCI) Clinical Trial

— AGING  

Official title:

The Potential Impact of Aging Stereotypes in the Assessment of Memory Deficits and Screening for Prodromal State of Alzheimer's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03138018
• Other study ID #: 2016-45
• Secondary ID: IDRCB Number
• Status: Recruiting
• Phase: N/A
• Start date: July 6, 2018
• Est. completion date: July 1, 2023

Study information

• Verified date: July 2018
• Source: Assistance Publique Hopitaux De Marseille
• Contact: Bernard MICHEL, PH
• Phone: 491744675
• Email: bmichel[@]ap-hm.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patients must be at least 50 years old

• Patients must report memory complaints

• Patients must show signs of MCI (amnestic single or multiple domain) on the following short cognitive tests

Exclusion Criteria:

• Probable Alzheimer's Disease according to NINCDS-ADRDA criteria (MA patients will be excluded from the study because false-positive errors only concern MCI status, not AD)

• Psychiatric disorders (schizophrenia, bipolar disorder)

• Cranial trauma

• Developmental pathologies

• Depression (score greater than or equal to 10 on GDS)

• Psychotropic medication if modified in the last 3 months

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Mild Cognitive Impairment (MCI)

Intervention

Diagnostic Test:
• Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuropsychological tests
• Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuroimaging biomarkers of neurodegeneration

Locations

Country	Name	City	State
France	Assistance Publique Hôpitaux de Marseille	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neuropsychological tests	Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)	48 months
Secondary	Neuroimaging biomarkers of neurodegeneration	Structural MRI (Hippocamp) and Florbetapir© PET (ß-amyloid deposition)	48 months
Secondary	Physiological stress	cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).	48 months
Secondary	Self-report questionnaires	Vulnerability factors for stereotyping threat effects are assessed	48 months
Secondary	Heart rate variability (thin elasticized heart rate transmitter belt),	Physiological stress	48 months
Secondary	Skin conductance (wristwatch)	Physiological stress	48 months
Secondary	Salivary biomarkers	cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).	48 months